ArticleDrug, healthcare and patient safety2026
Association of a CCB-Related Pharmacogenomics-Guided Strategy with Blood Pressure Outcomes and Short-Term Safety in Chinese Patients with Hypertension: A Secondary Exploratory Analysis of Two Randomized Cohorts.
Article in Drug, healthcare and patient safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Calcium channel blockers (CCBs) show notable interindividual variability in antihypertensive response. This study evaluated the association of a pharmacogenomics (PGx)-guided antihypertensive strategy incorporating Methods: This secondary exploratory analysis included patients receiving CCB-containing regimens from two previously completed multicenter randomized cohorts conducted in Hunan and Fujian provinces, China. The Hunan cohort assessed a 4-week PGx-guided strategy combined with structured management, while the Fujian cohort evaluated genotype-guided treatment during 4-8 weeks after an initial standardized management phase. The primary endpoint was BP control at the last follow-up; secondary endpoints included changes in systolic BP (SBP) and diastolic BP (DBP), medication use, and short-term safety outcomes. Multivariable regression models were used to adjust for prespecified clinical covariates. Results: A total of 4608 patients in Hunan and 418 patients in Fujian were included. In the Hunan cohort, the genotype-guided group had higher 4‑week BP control (81.83% vs 25.07%; adjusted OR = 14.56, P < 0.001) and greater SBP/DBP decreases. In the Fujian cohort, genotype-guided therapy was associated with higher 8‑week BP control (81.74% vs 77.39%; adjusted OR = 2.43, P = 0.003) and greater DBP decrease. Associations were stronger among patients whose BP remained uncontrolled after standardized management. No short-term safety concerns were identified. Conclusion: A genotype-guided antihypertensive strategy incorporating CCB-related PGx information, including
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.